GEN Exclusives

More »

GEN News Highlights

More »
Jan 7, 2010

Pfizer to Re-Test Failed Melanoma Drug in Phase III with Debiopharm

  • Pfizer has signed on Debiopharm Group to evaluate its melanoma drug candidate tremelimumab, which previously failed in Phase III. The companies’ co-development agreement for tremelimumab has Debiopharm responsible for the trial, while Pfizer retains rights to worldwide commercialization.

    An interim analysis done on tremelimumab, a fully human anti-CTLA4 mAb, during its last Phase III development program found that it would not offer any benefit over standard chemotherapy. Thus in April 2008, Pfizer was forced to halt the trial.

    A full evaluation of the data revealed a biomarker that predicted patients who were more likely to respond. The Phase III study to be conducted by Debiopharm will leverage this marker to select patients with unresectable, stage IV melanoma for enrollment.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?